Marker Therapeutics (MRKR) Change in Receivables (2011 - 2026)

Marker Therapeutics (MRKR) reported Change in Receivables of $7900.0 for Q1 2026, down 92.95% year-over-year from $112062.0 in Q1 2025, and down 92.95% quarter-over-quarter from $112062.0 in Q1 2025.

Marker Therapeutics (MRKR) Change in Receivables (2011 - 2026) Analysis & Trends

Marker Therapeutics (MRKR) has 4 years of Change in Receivables data on file, last reported at $7900.0 in Q1 2026.

  • Change in Receivables for Q1 2026 came in at $7900.0, down 92.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $119962.0 (up 7.11% YoY), and the FY2025 annual result was -$977303.0, down 174.1% from the prior year.
  • Change in Receivables slipped to $7900.0 in Q1 2026 per MRKR's latest filing, from $112062.0 in the prior quarter.
  • Over five years, Change in Receivables peaked at $112062.0 in Q1 2025 and troughed at $7900.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - 22,529.00
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn -39.80 Mn
9 Abivax 94.37 Bn 94.37 Bn - -4.08 Mn
10 Marker Therapeutics 28.20 Mn 28.20 Mn - 7,900.00

Historic Data

Download Data
DateValue
Mar 31, 2026 7,900.00
Mar 31, 2026 7,900.00
Mar 31, 2025 112,062.00
Mar 31, 2025 112,062.00
Jun 30, 2012 -24.00
Jun 30, 2012 -24.00
Mar 31, 2012 24.00
Mar 31, 2012 24.00
Jun 30, 2011 -65.00
Jun 30, 2011 -65.00
Mar 31, 2011 65.00
Mar 31, 2011 65.00